Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified–warmed blastocyst transfer cycles

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified–warmed blastocyst transfer cycles. / Polat, Mehtap; Mumusoglu, Sezcan; Bozdag, Gurkan; Ozbek, Irem Yarali; Humaidan, Peter; Yarali, Hakan.

I: Reproductive BioMedicine Online, Bind 40, Nr. 6, 2020, s. 812-818.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Polat, Mehtap ; Mumusoglu, Sezcan ; Bozdag, Gurkan ; Ozbek, Irem Yarali ; Humaidan, Peter ; Yarali, Hakan. / Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified–warmed blastocyst transfer cycles. I: Reproductive BioMedicine Online. 2020 ; Bind 40, Nr. 6. s. 812-818.

Bibtex

@article{057df7b7b5fa46b5bd7b173e87dd5828,
title = "Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified–warmed blastocyst transfer cycles",
abstract = "Research question: Does intramuscular progesterone supplementation ensure ongoing pregnancy rates (OPR) comparable with vaginal progesterone only in hormone replacement therapy cycles for vitrified–warmed embryo transfer; and is there a window of serum progesterone concentration out of which reproductive outcomes may be negatively affected? Design: Retrospective longitudinal cohort study carried out at a single IVF clinic. In total, 475 consecutive, day-5 to day-6 vitrified–warmed embryo transfer cycles using hormone replacement therapy regimen were included. Vaginal progesterone only was given to 143 patients; supplementation of vaginal progesterone only with intramuscular progesterone supplementation every third day was given to 332 patients. On the sixth day of progesterone administration, immediately before frozen–thawed embryo transfer, circulating progesterone levels were measured. Main outcome measure was OPR. Results: The baseline demographic features and embryological data of the vaginal progesterone only and intramuscular progesterone supplementation groups were comparable. The OPR were 48.3% and 51.8%, respectively (P = 0.477). Neither the circulating progesterone level nor the type of progesterone administration were independent predictors of OPR. The effect of serum progesterone levels on OPR was evaluated by percentiles (<10%, 10–49%, 50–90% and >90%), taking 50–90% as the reference sub-group. All percentiles in the intramuscular progesterone supplementation group and in the vaginal progesterone only group had similar OPR. Conclusions: Intramuscular progesterone supplementation every third day, overall, does not enhance OPR compared with vaginal progesterone only.",
keywords = "Cryopreserved embryo transfer, Hormone replacement therapy, Im progesterone supplementation, IVF, Serum progesterone, Vaginal progesterone supplementation",
author = "Mehtap Polat and Sezcan Mumusoglu and Gurkan Bozdag and Ozbek, {Irem Yarali} and Peter Humaidan and Hakan Yarali",
year = "2020",
doi = "10.1016/j.rbmo.2020.01.031",
language = "English",
volume = "40",
pages = "812--818",
journal = "RBM Online",
issn = "1472-6491",
publisher = "Reproductive Healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified–warmed blastocyst transfer cycles

AU - Polat, Mehtap

AU - Mumusoglu, Sezcan

AU - Bozdag, Gurkan

AU - Ozbek, Irem Yarali

AU - Humaidan, Peter

AU - Yarali, Hakan

PY - 2020

Y1 - 2020

N2 - Research question: Does intramuscular progesterone supplementation ensure ongoing pregnancy rates (OPR) comparable with vaginal progesterone only in hormone replacement therapy cycles for vitrified–warmed embryo transfer; and is there a window of serum progesterone concentration out of which reproductive outcomes may be negatively affected? Design: Retrospective longitudinal cohort study carried out at a single IVF clinic. In total, 475 consecutive, day-5 to day-6 vitrified–warmed embryo transfer cycles using hormone replacement therapy regimen were included. Vaginal progesterone only was given to 143 patients; supplementation of vaginal progesterone only with intramuscular progesterone supplementation every third day was given to 332 patients. On the sixth day of progesterone administration, immediately before frozen–thawed embryo transfer, circulating progesterone levels were measured. Main outcome measure was OPR. Results: The baseline demographic features and embryological data of the vaginal progesterone only and intramuscular progesterone supplementation groups were comparable. The OPR were 48.3% and 51.8%, respectively (P = 0.477). Neither the circulating progesterone level nor the type of progesterone administration were independent predictors of OPR. The effect of serum progesterone levels on OPR was evaluated by percentiles (<10%, 10–49%, 50–90% and >90%), taking 50–90% as the reference sub-group. All percentiles in the intramuscular progesterone supplementation group and in the vaginal progesterone only group had similar OPR. Conclusions: Intramuscular progesterone supplementation every third day, overall, does not enhance OPR compared with vaginal progesterone only.

AB - Research question: Does intramuscular progesterone supplementation ensure ongoing pregnancy rates (OPR) comparable with vaginal progesterone only in hormone replacement therapy cycles for vitrified–warmed embryo transfer; and is there a window of serum progesterone concentration out of which reproductive outcomes may be negatively affected? Design: Retrospective longitudinal cohort study carried out at a single IVF clinic. In total, 475 consecutive, day-5 to day-6 vitrified–warmed embryo transfer cycles using hormone replacement therapy regimen were included. Vaginal progesterone only was given to 143 patients; supplementation of vaginal progesterone only with intramuscular progesterone supplementation every third day was given to 332 patients. On the sixth day of progesterone administration, immediately before frozen–thawed embryo transfer, circulating progesterone levels were measured. Main outcome measure was OPR. Results: The baseline demographic features and embryological data of the vaginal progesterone only and intramuscular progesterone supplementation groups were comparable. The OPR were 48.3% and 51.8%, respectively (P = 0.477). Neither the circulating progesterone level nor the type of progesterone administration were independent predictors of OPR. The effect of serum progesterone levels on OPR was evaluated by percentiles (<10%, 10–49%, 50–90% and >90%), taking 50–90% as the reference sub-group. All percentiles in the intramuscular progesterone supplementation group and in the vaginal progesterone only group had similar OPR. Conclusions: Intramuscular progesterone supplementation every third day, overall, does not enhance OPR compared with vaginal progesterone only.

KW - Cryopreserved embryo transfer

KW - Hormone replacement therapy

KW - Im progesterone supplementation

KW - IVF

KW - Serum progesterone

KW - Vaginal progesterone supplementation

UR - http://www.scopus.com/inward/record.url?scp=85085123755&partnerID=8YFLogxK

U2 - 10.1016/j.rbmo.2020.01.031

DO - 10.1016/j.rbmo.2020.01.031

M3 - Journal article

C2 - 32362573

AN - SCOPUS:85085123755

VL - 40

SP - 812

EP - 818

JO - RBM Online

JF - RBM Online

SN - 1472-6491

IS - 6

ER -